Recent trials on two diabetes treatments have shown mixed results. Lixisenatide, developed by healthcare company Sanofi-Aventis, performed well in hitting a primary goal in a late stage study, while pharma giant Roche announced they were dropping the drug taspoglutide after disappointing phase III results.
Lixisenatide achieved its primary endpoint of non-inferiority in glucose reduction compared with exenatide (also known as Byetta ), which is manufactured by Eli Lilly . GetGoal-X examined 639 patients with type 2 diabetes, comparing lixisenatide, a once daily glucagon-like peptide-1 (GLP-1) receptor agonist against twice-daily exenatide as an add-on therapy for patients whose condition is inadequately controlled by metformin .
Pierre Chancel, head of diabetes research at Sanofi, commented “GetGoal-X, the first head-to-head study comparing lixisenatide with another GLP-1, demonstrates the efficacy of lixisenatide once-daily in reducing HbA1c in people with type 2 diabetes and also shows a better hypoglycemia profile.”
On the other hand, Roche has dropped its late stage diabetes drug taspoglutide, and will return the rights to the GLP-1 analogue drug to biotech company Ipsen . Clinical trials of taspoglutide were halted last September because of high instances of adverse side effects, such as hypersensitivity and nausea . Ipsen can now take ownership of the full data from the drug tests.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…